Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Triamcinolone hexacetonide
Drug ID BADD_D02274
Description Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis.[L8255] Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain,[L8264] or first line as a topical treatment of corticosteroid responsive dermatoses.[L8249] Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957.[L8243] In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval[L38973] - for the treatment of patients with macular edema associated with uveitis.[L38963]
Indications and Usage For the treatment of perennial and seasonal allergic rhinitis.
Marketing Status Prescription
ATC Code A01AC01; C05AA12; D07AB09; D07XB02; H02AB08; R01AD11; R03BA06; S01BA05
DrugBank ID DB00620
KEGG ID D00985
MeSH ID C005900
PubChem ID 21826
TTD Drug ID Not Available
NDC Product Code 52128-177; 46439-8728; 59137-570
Synonyms triamcinolone hexacetonide | 9-fluoro-11 beta,16 alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone, 21-(3,3-dimethylbutyrate) | Aristospan
Chemical Information
Molecular Formula C30H41FO7
CAS Registry Number 5611-51-8
SMILES CC1(OC2CC3C4CCC5=CC(=O)C=CC5(C4(C(CC3(C2(O1)C(=O)COC(=O)CC(C)(C)C)C)O)F)C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Muscle disorder15.05.03.014--Not Available
Muscular weakness15.05.06.001; 17.05.03.005--
Myocardial rupture02.04.02.002; 12.01.11.002--Not Available
Myopathy15.05.05.001--Not Available
Nausea07.01.07.001--
Neuritis17.09.03.001--Not Available
Neuropathic arthropathy17.09.03.008; 15.01.01.007--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Nitrogen balance negative13.13.01.010--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Osteonecrosis24.04.05.004; 15.02.04.007--
Osteoporosis15.02.03.002; 14.04.04.002--
Pancreatitis07.18.01.001--
Papilloedema06.09.02.002; 24.03.07.001; 17.07.02.004--
Paraesthesia17.02.06.005--
Paraparesis17.01.04.006--Not Available
Paraplegia17.01.04.007--Not Available
Pathological fracture16.32.03.007; 15.08.02.008; 12.04.02.006--Not Available
Peptic ulcer07.04.07.001--Not Available
Personality change19.05.01.006; 17.02.05.019--
Petechiae24.07.06.004; 01.01.03.002; 23.06.01.003--Not Available
Pulmonary oedema22.01.03.003; 02.05.02.003--
Rash23.03.13.001--Not Available
Secondary adrenocortical insufficiency05.01.02.003; 14.11.01.014--Not Available
Seizure17.12.03.001--
Sensory disturbance17.02.07.006--Not Available
Skin atrophy23.01.05.001--
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.003--Not Available
Skin hyperpigmentation23.05.01.003--
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages